Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague

Plague, Pneumonic Clinical Trial

— IMASOY  

Official title:

An Open-label, Randomised, Non-inferiority Trial of the Efficacy and Safety of Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin in the Treatment of Bubonic Plague

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04110340
• Other study ID #: 45-18
• Status: Recruiting
• Phase: Phase 3
• Start date: February 15, 2020
• Est. completion date: March 31, 2025

Study information

• Verified date: June 2024
• Source: University of Oxford
• Contact: Josephine Bourner
• Phone: +447385933832
• Email: josephine.bourner[@]ndm.ox.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this trial is to test the hypothesis that ciprofloxacin monotherapy given (orally, intravenously, or combination) for 10 days is non-inferior to an aminoglycoside (given on days 1-3) followed by ciprofloxacin (given on days 4-10) in the treatment of bubonic plague.

Secondary objectives are:

• to evaluate the level and kinetics of anti-Y. pestis antibodies of patients (bubonic and pneumonic plague) included in the study (anti-F1 ELISA techniques) at D1, D11, D21, M3 for patients who are positive at D21, and M12 for patients who are positive at M3.

The tertiary objectives are:

• to evaluate the level and kinetics of the levels of anti-Y. pestis antibodies and circulating F1 antigen of the patients (bubonic and pneumonic plague) included in the study (Luminex MagPix techniques with a Multiplex containing anti-F1 and rLcrV antigens and an F1 antigen capture multiplex) at D1, D11, D21, M3 for patients positive at D21, and M12 for patients who are positive at M3.

Observational non-comparative study of pneumonic plague

• The primary objective is to document the efficacy and safety of the currently recommended combination therapy treatment of pneumonic plague - an aminoglycoside (streptomycin or gentamicin) and ciprofloxacin combination therapy.

• The secondary and tertiary objectives of the bubonic plague trial also apply to the pneumonic plague cohort.

Description:

An individually randomised, open label, non-inferiority trial of ciprofloxacin versus an aminoglycoside and ciprofloxacin in patients with bubonic plague. We are using a non-inferiority design since the overall cure rate for bubonic plague without septicaemia with streptomycin is approximately 95%. As a result, demonstrating superiority would be unnecessary and impractical given the sample size that would be required. Our aim is therefore to demonstrate that ciprofloxacin alone is not more than 15% inferior to an aminoglycoside followed by ciprofloxacin. (15% is the non-inferiority margin in our study). We will recruit patients with a clinical suspicion of bubonic plague, but the size of our sample is powered based on an intention to treat infected patients sample size of 190, where infected is defined as a confirmed or probable case of bubonic plague. As a result the total number of patients to be enrolled will be higher than 190. We estimate that we will need to recruit approximately 600 patients with bubonic plague to achieve a sample size of 190 confirmed/probable bubonic plague patients. However, to mitigate risks of being under-powered we will propose to recruit for three full seasons with a minimum target of 190 confirmed/probable cases. Should we achieve the target of 190 confirmed/probable bubonic plague cases before the end of the final transmission season, we will nevertheless continue to recruit until the end of the season to retain power in the event of different treatment success percentages and to allow us to increase precision.

We will also recruit and collect data on patients with pneumonic plague, who will be enrolled in to a parallel observational cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 463
• Est. completion date: March 31, 2025
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria for randomisation to the bubonic plague treatment trial:

Bubonic plague

• Patients of any age AND

• Recent onset (< 10 days) of fever (uncorrected axillary temperature = 37.5C) or history of fever AND

• One or more buboes (tender lymph node swelling) AND

• Residence or travel to a plague endemic area in Madagascar within 14 days of the onset of symptoms AND

• Patients identified as clinically suspected of plague by health personnel (doctors or paramedics)

Exclusion Criteria to the bubonic plague treatment trial:

• Known allergy to aminoglycosides or fluoroquinolones

• Tendinitis

• Myasthenia gravis

• Theophylline or warfarin use

• Already treated for bubonic or pneumonic plague in the preceeding 3 months

• Women who report being pregnant

Inclusion of patients to the pneumonic plague observational cohort:

• Suspected, probable and confirmed cases of pneumonic plague

Related Conditions & MeSH terms

• Plague
• Plague, Bubonic
• Plague, Pneumonic

Intervention

Drug:
• Ciprofloxacin
Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days; Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days. Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.
• Streptomycin
Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days. Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days. Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.
• Gentamicin
Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days. Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days.

Locations

Country	Name	City	State
Madagascar	Professor Mamy Randria	Antananarivo

Sponsors (4)

Lead Sponsor	Collaborator
University of Oxford	Foreign, Commonwealth and Development Office and Wellcome (216273.Z.19.Z), Hôpital Universitaire Joseph Raseta Befelatanana CHU d'Antananarivo, Institut Pasteur de Madagascar

Country where clinical trial is conducted

Madagascar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with bubonic plague with a therapeutic response (assessed on day 11).Therapeutic response is defined as follows for subjects with a visible bubo:	Alive; Absence of fever; Has not received alternative treatment for plague; No clinical decision to continue anti-plague antibiotics beyond day 10	11 days
Secondary	Bubonic plague	• Proportion of patients without fever (uncorrected axillary temperature <37.5C) at Day 4	4 days
Secondary	Bubonic plague	• Proportion of patients with a pain score < 3 at Day 4 (using pain scale questionnaires)	4 days
Secondary	Bubonic plague	• Proportion of patients with a pain score < 3 at Day 11 (using pain scale questionnaires)	11 days
Secondary	Bubonic plague	• Mean % change in bubo size at Day 4 (measured by use of calipers and/or ultrasound)	4 days
Secondary	Bubonic plague	• Mean % change in bubo size at Day11 (measured by use of calipers and/or ultrasound)	11 days
Secondary	Bubonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 4	4 days
Secondary	Bubonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 11	11 days
Secondary	Bubonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 21	21 days
Secondary	Bubonic plague	• Proportion of patients who are fully adherent to the study treatment schedule.	21 days
Secondary	Pneumonic plague	Proportion of patients with a therapeutic response at Day 11. Therapeutic response is defined as follows: Alive; Resolution of fever (uncorrected axillary temperature <37.5C); Resolution of tachypnoea (RR< 24 in adults, but age-specific in children)	11 days
Secondary	Pneumonic plague	• Proportion of patients without fever (uncorrected axillary temperature <37.5C) at Day 4	4 days
Secondary	Pneumonic plague	• Proportion of patients with tachypnoea resolution (RR< 24 in adults, but age-specific in children) at Day 4	4 days
Secondary	Pneumonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 4	4 days
Secondary	Pneumonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 11	11 days
Secondary	Pneumonic plague	• Proportion of patients experiencing a serious adverse event on or before Day 21	21 days
Secondary	Pneumonic plague	• Proportion of patients who are fully adherent to the study treatment schedule.	21 days
Secondary	Therapeutic response is defined as follows for subjects with a visible bubo:	Alive AND; Absence of fever at D11 AND; At least a 25% decrease in bubo size (in the case of multiple buboes, the largest bubo) AND; Has not received alternative treatment for plague AND; No clinical decision to continue anti-plague antibiotics beyond day 10; ? Therapeutic response is defined as follows for subjects with small buboes that are palpable but not measurable: Alive AND; Absence of fever at D11 AND; Bubo has not enlarged AND; Has not received alternative treatment for plague AND; No clinical decision to continue anti-plague antibiotics beyond day 10	11 days